PhRMA

By Israel Rocha, CEO, Doctors Hospital at Renaissance September 15 marks the beginning of Hispanic Heritage Month, a time to pay tribute to the generations of Hispanics who have enriched America’€™s history. It’€™s also an important time to consider how this community can be further empowered to make important contributions, particularly in the future of health care. Research demonstrates that certain diseases disproportionately impact the Hispanic community, including diabetes, liver cancer, cervical cancer and HIV/AIDS. Clinical trials help researchers find better ways to diagnose, prevent and treat these diseases and others. However, Hispanics are significantly underrepresented in...
Dear Research Advocate: In recognition of his many accomplishments as a champion for research, Research!America Chair and former Congressman John Edward Porter was honored by the National Academy of Sciences with the Public Welfare Medal, the Academy’€™s most prestigious award. This well-deserved acknowledgment of Porter’€™s tireless efforts to advance innovation and engage scientists in advocacy should motivate advocates to follow his lead and speak up about threats to our nation’€™s research ecosystem. Read our statement on the award ceremony here . In his remarks , Mr. Porter noted that ’€œpolitical judgment should never be allowed to be substituted for scientific judgment.’€ This point...
Dear Research Advocate: Fostering research and innovation has long been a multi-pronged effort ’€” government, industry, academia, patients and patient organizations, foundations, and individual philanthropists ’€” all working to advance research. The current interest shown by private philanthropists in advancing science is an echo of a phenomenon witnessed a century ago ’€” and a sign of the opportunity available in some way to all of us to accelerate medical progress and maintain our nation’€™s competitive edge. As reported in a recent front page New York Times article, private donors are stepping up in a big way at a time when scientific opportunity has never been greater. But it is...
by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’€™s Conversations forum. A shift in attitude among elected officials is necessary if this nation is to succeed in combating disease and stemming the rise of health care costs. Federal funding for the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other agencies that conduct medical and health research has not kept pace with scientific opportunity, jeopardizing our ability to find cures for deadly disease and to maintain our global competitive edge. Medical research has not risen to the upper ranks of our nation’€™s priorities in the halls...
by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’€™s Conversations forum. A shift in attitude among elected officials is necessary if this nation is to succeed in combating disease and stemming the rise of health care costs. Federal funding for the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other agencies that conduct medical and health research has not kept pace with scientific opportunity, jeopardizing our ability to find cures for deadly disease and to maintain our global competitive edge. Medical research has not risen to the upper ranks of our nation’€™s priorities in the halls...
Pending Budget Cuts will Further Jeopardize Global Leadership in Research and Innovation WASHINGTON, DC ’€”October 25, 2012’€”Biomedical and health research and development (R&D) spending from all sources declined by more than $4 billion or 3% between FY10 and FY11 according to Research!America’€™s 2011 U.S. Investment in Health Research report. This represents the first drop in overall spending since Research!America began compiling the data in 2002. The decline follows an uptick in research funding attributed to the American Recovery and Reinvestment Act (ARRA), which allocated $10.4 billion to the National Institutes of Health (NIH) over two fiscal years (2009-2010). The overall...
The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a new initiative which focuses on the myriad benefits of health and medical research, particularly as it relates to patient care. The initiative, titled From Hope to Cures , uses patient videos as well as statistical evidence and graphics to illustrate how the billions of dollars spent by pharmaceutical companies on research are extending and enriching the lives of millions of people. This new initiative represents a push for research, progress, and hope. There are numerous items on the initiative’€™s website including links to articles ranging from drug discovery and development to a study which predicts...

Sidebar Quote

Public sentiment is everything. With public sentiment, nothing can fail; without it nothing can succeed.
Abraham Lincoln